NervGen Pharma Corp. NGEN
1.33 USD -0.06 (-4.66%)
At closeNov 10, 2026, 7:21 PM EST
1.33 0.00 +0.05%
After hours · Nov 10, 7:21 PM ET
1.32 Day range 1.41
1.28 52-week range 6.30
- YTD
- -76.25%
- 1 year
- -44.58%
- Market cap
- 143.01M
- EPS (ttm)
- -0.57
- YTD return
- -76.25%
- 1-year return
- -44.58%
- Volume
- 281.45K
- Avg volume
- 511.18K
- Open
- 1.39
- Previous close
- 1.40
- Day's range
- 1.32 – 1.41
- 52-week range
- 1.28 – 6.30
5D +0.05 (+3.73%)
Financials — quick view
NGEN Revenue — quarterly 0
NGEN Net income — quarterly 10.80M
NGEN EPS — quarterly 0.12
News
NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028 
NervGen Pharma: The Upside Is Large, But Phase 3 Decides Everything 
NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript 
NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026 
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments 
NervGen to Host Inaugural R&D Day on September 30, 2026 
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates 
Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday 
HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15 - Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10
Your note
Sign in to keep a note on NGEN — it syncs with the Stock Master app.